A Phase I Trial of ACX-362E for the Treatment of Clostridium difficile Infection (CDI)
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
At a glance
- Drugs ACX 362E (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man
- Sponsors Acurx Pharmaceuticals
- 16 Jan 2019 According to an Acurx Pharmaceuticals media release, ACX-362E has recently entered this trial.
- 16 Jan 2019 Status changed from planning to recruiting, according to an Acurx Pharmaceuticals media release.
- 26 Jun 2018 New trial record